Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide. Tobacco use is the main risk factor for HNSCC, and tobaccoassociated HNSCCs have poor prognosis and response to available treatments. Recently approved anti-PD-1 immune checkpoint inhibitors showed limited activity (≤20%) in HNSCC, highlighting the need to identify new therapeutic options. For this, mouse models that accurately reflect the complexity of the HNSCC mutational landscape and tumor immune environment are urgently needed. Here, we report the first mouse HNSCC model system that recapitulates the human tobacco-related HNSCC mutanome, in which tumors grow when implanted in the tongue of immunocompetent mice. These HNSCC lesions have similar immune infiltration and response rates to anti-PD-1 (≤20%) immunotherapy as human HNSCCs. Remarkably, we found that >70% of HNSCC lesions respond to intratumoral anti-CTLA-4. This syngeneic HNSCC mouse model provides a platform for the development of novel immunotherapeutic options for HNSCC.
Introduction
Tobacco smoking claims the lives of more than 6 million people every year worldwide and is the leading cause of cancer deaths in the U.S 1, 2 . Tobacco use has been associated with at least 17 types of cancer, primarily in the lung, as well as with carcinomas arising in the oral cavity, pharynx, and larynx, often referred to as squamous cell carcinomas of the head and neck (HNSCC) 1, 2 . HNSCC is a significant public health issue, with more than 65,400 new cases resulting in 14,600 deaths in 2019 in the U.S. alone 3 . The main risk factors include tobacco use and human papillomavirus (HPV) infection, the latter of which is predicted to diminish in the future due to successful vaccination campaigns 4, 5 . Depending on the stage of disease, HNSCC is typically treated with surgery, radiotherapy, chemotherapy, or a combination of these interventions. These standard therapies result in a five-year survival of approximately 63%, but patients with more advanced stages have higher rates of mortality (5 year survival <50%) and require multimodality treatments, which can lead to occurrence of significant long-term side effects and lower quality of life 6, 7 . Despite this more aggressive regimen, up to 30-60% of HNSCC patients develop tumor recurrence, and often succumb to the disease 8 . The recent elucidation of the genomic alterations underlying HNSCC progression and new immunotherapeutic strategies may provide an opportunity for the development of more effective treatment options for HNSCC.
Revolutionary breakthrough discoveries in cancer immunology have demonstrated that a patient's own immune cells can be manipulated to target, attack, and destroy cancer cells [9] [10] [11] . A key emerging mechanism of tumor immune evasion involves T cell exhaustion, whereby T cell reactivity is impaired due to activation of T cell checkpoints, including PD-1 by its ligand, PD-L1 that is expressed by macrophages and some cancer cells, including HNSCC, restraining T cell activation (reviewed in 12 ). Indeed, immune checkpoint blockade (ICB) by new immunotherapeutic agents such as pembrolizumab and nivolumab (anti-PD-1) have recently demonstrated potent anti-tumor activity in a subset of HNSCC patients [13] [14] [15] [16] . However, one-year survival and response rates of anti-PD-1 in HNSCC were only 36% and 14%, respectively, which highlights the urgent need to identify novel therapeutic options to increase the effectiveness of ICB for the >80% of patients that do not have an objective response to anti-PD-1/PD-L1 treatment [13] [14] [15] .
Animal models with a full functioning immune system that also properly resemble human HNSCC etiology and mutational landscape are desperately needed to accurately recapitulate the complexity of the tumor immune microenvironment (TIME), thereby accelerating the search for new immune therapeutic options. Here, we report the first syngeneic murine HNSCC cell panel that recapitulates typical human tobacco-related HNSCC genomic alterations and mutational landscape, and we show that these cells form squamous carcinomas (HNSCC) when implanted orthotopically in the tongue of immune competent C57Bl/6 mice. These HNSCC lesions have immune infiltration and response rates to anti-PD-1 therapies (≤20%) similar to those of human HNSCCs, thereby providing a platform for the evaluation of new immune oncology (IO) options for HNSCC treatment.
Results

Novel syngeneic HNSCC animal models exhibiting tobacco carcinogen-related mutational signatures and genomic landscape.
Tobacco smoke contains a number of harmful carcinogens that drive tumorigenesis, the exposure to which strongly correlates with cancer incidence 17 .While tobacco-associated cancers are generally characterized by high mutation frequencies 18 , we have recently reported that they can be defined by very specific set of mutational signatures 19 . We have also described the optimization of a carcinogen-induced oral cancer mouse model in which the compound 4-nitroquinoline-1 oxide (4NQO), a DNA adduct-forming agent that causes DNA damage and promotes oral cancer initiation and progression 20 . This model has been used extensively to study HNSCC progression and preventive and treatment therapeutic options [21] [22] [23] . However, its direct relevance to human HNSCC has not been previously established. To begin developing syngeneic HNSCC animal models, we first isolated 4 representatives murine HNSCC cell lines from primary 4NQO-induced tumors in the tongue of C57Bl/6 mice (designated 4MOSC1-4, short for 4NQO-induced Murine Oral Squamous Cells) ( Fig. 1a) . The use of SigProfiler 24,25 to analyze exome DNAseq of these HNSCC cells revealed a remarkable 93.9 % similarity with human cancer signature 4, which is strictly associated with tobacco smoking, including in HNSCC, esophageal cancer, and lung cancer 19 (Pearson correlation > 0.93) ( Fig. 1b and individual 4MOSC cells in Supplementarly Fig 1) . This similarity between 4NQO-induced mutational patterns and tobacco extended to the presence of a transcriptional strand bias ( Fig. 1c) , which reflects rate of substitution type on each nucleotide. In contrast, the mutational signature of SCC caused by DMBA, a carcinogen found in tobacco smoke that is the most widely used agent for experimental carcinogenesis studies 26 , showed only 39.7% similarity with human cancer signature 4.
This suggests that 4NQO-induced SCC lesions better reflect human tobacco-related human HNSCC. Indeed, these cells also exhibit typical HNSCC histology and mutations impacting Trp53, Fat1-4, Keap1, Notch1-3, Kmt2b-d, and others, which represent some of the most frequently altered gene pathways in HPV-human HNSCC ( Fig. 1d -e, and Supplementary Table 1 ). Of note, similar to HPV(-) HNSCC samples from TCGA, all four 4MOSC cells exhibit typical inactivating Trp53 mutations in its core DNA binding domain, including hot spot residues (G245, and R248) that result in loss of tumorsuppression and gain of tumorigenesis and invasiveness 27 .
Orthotopic oral SCC lesions reflect the complexity of the human HNSCC tumor immune microenvironment (TIME), including exhausted-CD8 T cell infiltration.
Transplantation of the 4MOSC cells orthotopically into the tongue of immunocompetent C57Bl/6 mice led to the formation of well-differentiated HNSCC tumors in two of the cell lines, 4MOSC1 and 4MOSC2, which exhibit typical HNSCC histology, as indicated by hematoxylin and eosin (H&E) stained sections and fluorescence cytokeratin 5 staining ( Fig. 2a and Supplementary Fig. 2a ). 4MOSC3 and 4MOSC4 cells also formed tumors, but they regressed spontaneously after 2 weeks. This is likely due to their rejection by the host immune system, as judged by their continuous growth upon CD8 T cell depletion (not shown). Thus, we focused our studies on 4MOSC1 and 4MOSC2, with emphasis on investigating whether they have distinct biological properties reflecting human HNSCC.
In this regard, since HNSCC has a high propensity to metastasize to locoregional lymph nodes (reviewed in 28 ), leading to poor prognosis, we next addressed the metastatic potential of our model. Histological evaluation in H&E stained sections revealed growth of cancer cells in the lymph nodes of mice bearing 4MOSC2 but not 4MOSC1 tumors ( Fig. 2b) . 4MOSC2 tumors also exhibited much higher density of lymphatic vessels staining positive for LYVE-1 than in 4MOSC1 ( Fig. 2c) , which is aligned with the strong correlation between intratumoral lymphangiogenesis and metastasis in human HNSCC (reviewed in 29 ).
By flow cytometry analysis, we found that the immune cells infiltrating the TIME comprises of cytotoxic T cells (CD8), helper T cells (CD4), regulatory T cells (Treg), natural killer cells (NK), macrophages (M1Φ and M2Φ), as well as polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC), and monocytic myeloid-derived suppressor cells (M-MDSC) 30 ( Fig. 2d) . Notably, although the ratios of immune infiltration were similar, 4MOSC2 tumors had a considerably higher level of infiltration than 4MOSC1 ( Fig. 2d) . Though cytotoxic CD8 T cells infiltrate both tumors at similar proportions relative to other immune cells, immunofluorescence staining showed more abundant distribution within 4MOSC2 tumor cells ( Fig. 2e) . To determine whether this immune infiltration is associated with antigen-driven immunogenicity, we next investigated whether the 4MOSC tumors could generate memory immune responses. Initial exposure of mice to tumor cell antigens was achieved by first irradiating tumor cells and then injecting into the tongue of C57Bl/6 mice with or without polyinosinic-polycytidylic acid (poly IC) as an immune adjuvant. Irradiated 4MOSC1 and 4MOSC2 cells did not form tumors, and mice vaccinated with irradiated tumor cells alone or irradiated tumor cells with poly IC failed to form tumors when they were subsequently re-challenged with non-irradiated cancer cells, while naïve mice and mice with poly IC alone still formed tumors. This suggests that the mice were able to develop an immunological memory to 4MOSC antigens even in the absence of an immune adjuvant, indicating that these syngeneic HNSCC cell lines are highly immunogenic ( Supplementary Fig. 2b-e ).
These findings indicate that these mice are capable of generating adaptive immune responses against 4MOSC tumor antigens. However, 4MOSC tumors still grow and lead mice to succumb to disease, implying that these tumors can evade immunity by inducing an immune suppressive microenvironment. The expression of programmed death ligand 1 (PD-L1), the ligand for the T-cell inhibitory receptor PD-1, is often high in HNSCC patients (46-100% of tumors) 31 and has been shown to suppress cytotoxic T cells that destroy tumors and also serves as a biomarker (reviewed in 32 ) predicting a better response to anti-PD-1 therapy. We found that PD-L1 is constitutively expressed on both tumor (CD45 -) and immune cells (CD45 + ), but the frequency of 4MOSC1 tumor cells that expressed PD-L1 was much higher than the frequency of 4MOSC2 cells expressing PD-L1 ( Fig. 2f) . Activated (CD44 + ) CD8 T cells infiltrating both 4MOSC1 and 4MOSC2 tumors exhibited characteristic T-cell exhaustion markers, PD-1, cytotoxic T lymphocyte associated protein 4 (CTLA-4), T-cell immunoglobulin mucin 3 (TIM-3), and lymphocyte activation gene 3 (LAG-3) ( Fig. 2g) . Interestingly, there were higher T-cell exhaustion markers in tumor-infiltrating lymphocytes (TILs, green) than in lymph nodes (blue) or blood (red) in both tumors ( Fig. 2g ).
Most syngeneic HNSCC tumors are refractory to anti-PD-1 immune checkpoint blockade.
To interrogate whether blocking the interaction of PD-1 and PD-L1 could cause tumor regression, we first studied 4MOSC1 tumors, the syngeneic HNSCC cell line that has higher PD-L1 expression. Most mice showed an initial decreased tumor volume after anti-PD-1 treatment ( Fig. 3a) , with a consequent increased overall survival ( Fig. 3b) (p<.001). Interestingly, however, 75% of mice that initially responded to anti-PD-1 (partial response, PR) showed tumor relapse and eventually succumbed to disease burden, while 10-20% of the mice showed complete responses (CR) ( Fig. 3a-b , and Supplemental Fig.   3a ). 4MOSC1 tumors from mice treated with anti-PD-1 showed significantly higher CD8 infiltration (p<0.01) compared to tumors from untreated mice by FACS analysis of tumor infiltrating leukocytes (TILs) and by immune fluorescence analysis of treated tissues ( Fig.   3c and 3d, respectively). All responses to anti-PD-1 were abolished if CD8 T cells were eliminated from mice ( Fig. 3e and Supplemental Fig. 3b ). Together, these data indicate a CD8-dependent anti-PD-1 response in mice with 4MOSC1 tumors, but with limited durable disease control or tumor regression, which is similar to the clinical response to anti-PD-1 therapies in HNSCC patients 14, 16 . To our surprise, although metastasis was not observed in 4MOSC1 control mice (see above), the cervical lymph nodes of CD8depleted mice with 4MOSC1 tumors showed tumor invasion, as indicated by cytokeratin 5 staining ( Fig. 3f ) and visualization with H&E-staining (Supplemental Fig. 3c) suggesting that immune surveillance may prevent the metastatic spread of this tumor. In contrast, mice bearing 4MOSC2 tumors failed to respond to anti-PD-1 treatment ( Fig. 3g and Supplemental Fig. 3d ), suggesting 4MOSC2 serves as a less differentiated, high immune cell-infiltrated, metastatic, and PD-L1-low, and anti-PD-1 resistant model ( Fig.   3g , and Supplemental Fig. 3d ).
Immune regulatory activity of intratumoral (in situ) delivery of ICB antibodies
A defining feature of most HNSCCs is the superficial and mucosal localization of the disease. Unlike many other cancer types, most HNSCC patients have tumors that can be readily visualized and accessed by surgeons, providing an opportunity to use intratumoral (IT) drug delivery. To investigate whether IT injection of anti-PD-1 has improves activity in our model, we compared the effectiveness of using a lower dose anti-PD-1 treatment with standard systemic delivery. We found that mice treated with just half the dose of anti-PD-1 locally showed similar anti-tumor responses compared to mice with full dose systemic treatment ( Fig. 4a) . Furthermore, immunofluorescence analysis revealed that IT delivery led to significantly higher PD-1 antibody distribution in tumors and cervical lymph nodes and lower distribution in the spleen as a peripheral organ when compared to systemic delivery ( Fig. 4b) .
To investigate if there are local, differential immune signature alterations associated with IT drug delivery, we performed a comprehensive immune profiling using the nCounter PanCancer Mouse Immune Profiling gene expression platform (NanoString Technologies). Using 770 immune-related genes, we profiled immune cells infiltrating the tumor following treatment with systemic or intratumoral anti-PD-1, and compared it with another FDA-approved immunotherapy, CTLA-4 blockade. Relative to the tongues from healthy mice, mice bearing 4MOSC1 tumors have elevated expression of a majority of immune cell-associated genes. While systemic anti-PD-1 treatment increased the T cell signature, IT delivery enhanced it further while also increasing gene expression of natural killer cells and genes related to cytotoxic immune cells ( Fig. 4c) . Interestingly, albeit used initially as a control, this analysis revealed that IT treatment with anti-CTLA-4 led to even more robust T cell, cytotoxic cell, and macrophage responses. In addition, while anti-PD-1 increased Treg associated gene signatures, anti-CTLA-4 appears to diminish it ( Fig.   4c-d) .
Complete response to anti-CTLA-4 ICB in the majority of 4MOSC1 syngeneic
HNSCC lesions
Given that immune stimulatory effects were enhanced following anti-CTLA-4 treatment compared to anti-PD-1 treatment, we sought to determine whether mice with 4MOSC1 tumors can also respond to CTLA-4 blockade. CTLA-4 blockade systemically and IT elicited a robust anti-tumor effect, with 90% of the mice exhibiting a CR ( Fig. 5a and Supplemental Fig. 4a ) and efficiently resisted engraftment when re-challenged with fresh 4MOSC1 cells (data not shown). Similar to anti-PD-1 treatment, IT delivery resulted in significantly higher anti-CTLA-4 antibody distribution in tumors and cervical lymph nodes and lower distribution in the spleen (Fig. 5b) . Anti-tumor immunity of anti-CTLA-4
is also CD8 dependent, as CTLA-4 inhibition resulted in significantly increased infiltration of CD8 + T cells (Fig. 5c) , and its anti-tumor activity was abolished by depletion of CD8 T cells (Supplemental Fig. 4b ). Additionally, flow cytometry analysis of the tumor revealed that following treatment with anti-CTLA-4, there is a significant decrease in immunosuppressive regulatory FoxP3 + T cells (Tregs) ( Figs. 5c and 5d) . In contrast to the effect of anti-CTLA-4, anti-PD-1 treatment led to significant increases in Tregs and FoxP3 expression in the TILs. Of interest, 4MOSC2 tumors also failed to respond to anti-CTLA-4 treatment (Supplemental Fig. 4c ), providing a model that is resistant to both forms of immunotherapy for future exploration of immunotherapy resistance and the use of strategic combinatorial modalities.
Discussion
HNSCC is an immunosuppressive disease, in which the tumor deploys multiple mechanisms to evade immune surveillance and antitumor immune responses through the accumulation of immunosuppressive cytokines, impairment of cytotoxic activity and antigen-presenting function, and induction of T cell exhaustion (reviewed in 12 ). Based on this knowledge, numerous immunotherapeutic strategies were developed, including ICB, cancer vaccines, therapeutic cytokines, adoptive T-cell transfer, and adjuvants that may trigger innate immune responses such as TLR and STING agonists (reviewed in 12 Tobacco use is one of the major risk factors for initiation and progression of HNSCC, and serves as an important prognostic factor for survival and mortality after cancer diagnosis (reviewed in 33 ). In a recent study, we analyzed somatic mutations and DNA methylation in 5243 samples comprising of cancers for which tobacco smoking confers an elevated risk, which helped define the human tobacco-associated cancer signature 19 . Remarkably, although tobacco smoke is made up of thousands of chemicals, including more than 60 carcinogens 17 , we found that 4NQO exposure was sufficient to mimic the tobacco carcinogenic signature. This is supported by compelling evidence demonstrating that 4NQO-induced SCC lesions exhibit near identical association (~94%) with the tobacco mutational landscapes, recapitulating human HNSCC. This is in contrast with the mutational signature caused by DMBA (<40% similarity), which although representing a widely used tobacco carcinogen 26 , may not be as effective as 4NQO in reflecting the human tobacco-associated genetic signatures 19 .
In this regard, currently available syngeneic HNSCC models include SCCVII cells, Seminal studies have shed light on T cell exhaustion in human cancers, where CD8 T cells lose proliferative capacity, the ability to produce tumor necrosis factor (TNFα), interleukin-2 (IL-2), and interferon-γ (IFNγ), and upregulation of inhibitory checkpoint receptors, such as PD-1 and CTLA-4 [9] [10] [11] . Recently, the successes of ICB to reverse T cell exhaustion in multiple cancers illustrates the potential of therapeutic strategies targeting these negative regulatory pathways 38 . In the clinic, PD-1 blockade offers 10~20% clinical improvement in HNSCC [13] [14] [15] , which was modeled similarly in our study where anti-PD-1 led to regression of 4MOSC1 tumors in only ≤20% of mice. The increase in CD8 T cells seemed to provide only temporary cytotoxic activity in mice treated with anti-PD-1, as we observed reoccurrence of tumors in the majority of treated mice. Surprisingly, we saw enhanced anti-tumor responses with anti-CTLA-4 treatment, where most 4MOSC1 tumor bearing mice showed complete responses and no tumor reoccurrence. The resulting increase in CD8 T cells following anti-CTLA-4 treatment confirmed that targeting checkpoints may revitalize immunological effect of exhausted T cells, at least at the cellular level. One explanation for these strikingly different responses could be that PD-1 blockade may induce compensatory upregulation of FoxP3 + Treg cells 39, 40 , as it occurred in our anti-PD-1-treated mice but not in anti-CTLA-4-treated mice. In fact, CTLA-4 inhibition led to significantly lower levels of FoxP3 + Treg cells in the tumors. In this regard, while both blocking antibodies can lead to cytotoxic CD8 T cell responses, anti-CTLA-4 may provide additional anti-tumor immunity by depleting Tregs that mediate an immunesuppressive environment (reviewed in 41 ). Moreover, PD-1 blockade predominantly activates T cells within the tumor, whereas anti-CTLA-4 may activate T cells primarily in the lymph nodes 41 , in which high levels of anti-CTLA-4 can be achieved by IT delivery.
These and yet to be identified mechanisms may underlie the increased response to anti-CTLA-4 in some anti-PD-1 refractory HNSCC lesions, whose elucidation may provide biomarkers for the selection of patients that may benefit from anti-CTLA-4 treatment after failing to anti-PD-1 therapy.
One limitation of using anti-CTLA-4 for HNSCCs in the clinic is its toxicity 42 .
Systemic delivery of IO agents have been shown to be responsible for severe immune related adverse events (irAEs), such as colitis, dermatitis, uveitis, and hypophysitis 42 .
These adverse events are very toxic, at times irreversible and can even be life-threatening.
With this in mind, IT injection may enhance tumor-specific T cell responses while reducing significant systemic exposure to healthy tissue and off-target toxicities 43, 44 . In addition, IT immunotherapy usually causes in situ priming of antitumor immunity, which may allow a patient's own tumor cells to be used as a therapeutic vaccine 43, 44 . In our study, a lower dose of IT anti-PD-1 showed similar therapeutic effects as systemic delivery of a higher dose, and IT anti-CTLA-4 led to complete regression of most 4MOSC1 tumors that are primarily refractory to anti-PD-1. Additionally, IT injection led to higher distribution of the antibody in the tumor and cervical lymph nodes, but less in the spleen as a surrogate for distribution in peripheral organs. This suggests that the IT route, which is feasible in HNSCC, may serve as a more effective and less toxic therapeutic strategy for this tumor type, a possibility that may have readily applicable clinical implications, and hence warrant further investigation.
Certainly, some HNSCC tumors have minimal immune infiltration, and may require a multipronged approach to facilitate immune recruitment and activation of the anti-tumor immune response 45, 46 . Other HNSCC lesions are completely refractory to ICB, even if highly immune infiltrated. In this regard, mice implanted with 4MOSC2 failed to respond to anti-PD-1 and anti-CTLA-4 therapy, likely due to the presence of abundant immune suppressive MDSC 30 in the TIME, which may restrict DC and/or CD8 + T cell function in addition to promoting T cell exhaustion. Therefore, this 4MOSC model system is ideal for investigating mechanisms of immunotherapy resistance, as well as testing novel multimodal immunotherapies and/or optimization of potential combinations of ICB with chemo-and radiotherapies. Altogether, our findings suggest that our novel syngeneic HNSCC animal models, which strongly reflect tobacco-associated HNSCC and typical clinical situations, may provide experimental tools to investigate interplays between HNSCC and the immune system as well as provide unique opportunities to identify more effective therapeutic strategies for tobacco-associated HNSCC, which are associated with poor prognosis and reduced response to most currently available treatment options. Fluorochrome-conjugated antibodies were purchased from BioLegend and BD Biosciences.
Materials and Methods
Reagents
Establishment of cell lines and tissue culture
Female C57Bl/6 mice (4-6 weeks of age and weighing 16-18g) were purchased from Charles River Laboratories (Worcester, MA, USA). 4NQO was diluted in the drinking water to a final concentration of 50 μg/mL to animals and was changed weekly. After 16 weeks, all animal cages were reverted to regular water until week 22. Animals were euthanized on week 22 for tissue retrieval. Single lesions were dissected and digested into a single cell suspension according to the protocol in Supplemental Materials.
DNA sequencing, genomic data analysis, and tobacco signature analysis
Raw sequencing data were aligned to the mm10 reference genome using BWA 47 . Gene mutation analyses were performed comparing our 4 syngeneic cells to a HNSCC provisional dataset containing 243 HPV-negative tumor samples from the publicly available consortium, The Cancer Gene Atlas (TCGA) 37 . Mutational plots of p53 mutations observed in characterized HNSCC samples from TCGA and 4 of our syngeneic cell lines were summarized using the 'lolipop' mutation diagram generator 51 .
In vivo mouse experiments and analysis
All the animal studies using HNSCC tumor xenografts and oral carcinogenesis studies were approved by the Institutional Animal Care and Use Committee (IACUC) of University of California, San Diego, with protocol ASP #S15195. 4MOSC1 and 4MOSC2 cells were transplanted (1 million per mouse) into the tongue of female C57Bl/6 mice (4-6 weeks of age and weighing 16-18g). When tumors were formed (on day 5-6), the mice were first randomized into groups. For drug treatment, the mice were treated by either intraperitoneal (IP) or intratumoral (IT) injection with isotype control antibody, PD-1 antibody, or CTLA-4 antibody (IP 10mg/kg, IT 5mg/kg, three times a week) for three weeks. The mice were then euthanized after the completion of the treatment (or when control-treated mice succumbed to tumor burdens, as determined by the ASP guidelines) and tumors were dissected for flow cytometric analysis or histologic and immunohistochemical evaluation.
Immunofluorescence and image quantification
All tissue samples were processed and stained as previously described 52 . Briefly, tissues (tongue, cervical lymph nodes and spleen) were harvested, fixed, and paraffin embedded. 
NanoString analyses
RNA was isolated from tumor samples using the RNeasy Micro Kit (Qiagen 74004). 
Hybridization of samples was done according to the NanoString Hybridization
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request. Hecht smoking. The somatic mutational profiles of the four lesions from mice exposed to 4NQO were correlated to known mutational signatures in human cancer (Pearson correlation > 0.93) 19,24 . Top, Signature 4 extracted from cancers associated with tobacco smoking, this signature was found only in cancer types in which tobacco smoking increases risk and mainly in those derived from epithelia directly exposed to tobacco smoke 19 ; Middle, the pattern of a mutational signature of lesions from mice exposed to 4NQO, compilation of all 4 samples analyzed; Bottom, the pattern of a mutational signature of lesions from mice 
Figure Legends
Figure 1 A A A A C C C C G G G G T T T T C C C C C C C C C C C C C C C C A C G T A C G T A C G T A C G T A A A A C C C C G G G G T T T T C C C C C C C C C C C C C C C C A C G T A C G T A C G T A C G T A A A A C C C C G G G G T T T T C C C C C C C C C C C C C C C C A C G T A C G T A C G T A C G T A A A A C C C C G G G G T T T T T T T T T T T T T T T T T T T T A C G T A C G T A C G T A C G T A A A A C C C C G G G G T T T T T T T T T T T T T T T T T T T T A C G T A C G T A C G T A C G T A A A A C C C C G G G G T T T T T T T T T T T T T T T T T T T T A C G T A C G T A C G T A C G T A A A A C C C C G G G G T T T T C C C C C C C C C C C C C C C C A C G T A C G T A C G T A C G T A A A A C C C C G G G G T T T T C C C C C C C C C C C C C C C C A C G T A C G T A C G T A C G T A A A A C C C C G G G G T T T T C C C C C C C C C C C C C C C C A C G T A C G T A C G T A C G T A A A A C C C C G G G G T T T T T T T T T T T T T T T T T T T T A C G T A C G T A C G T A C G T A A A A C C C C G G G G T T T T T T T T T T T T T T T T T T T T A C G T A C G T A C G T A C G T A A A A C C C C G G G G T T T T T T T T T T T T T T T T T T T T A C G T A C G T A C G T A C G T A A A A C C C C G G G G T T T T C C C C C C C C C C C C C C C C A C G T A C G T A C G T A C G T A A A A C C C C G G G G T T T T C C C C C C C C C C C C C C C C A C G T A C G T A C G T A C G T A A A A C C C C G G G G T T T T C C C C C C C C C C C C C C C C A C G T A C G T A C G T A C G T A A A A C C C C G G G G T T T T T T T T T T T T T T T T T T T T A C G T A C G T A C G T A C G T A A A A C C C C G G G G T T T T T T T T T T T T T T T T T T T T A C G T A C G T A C G T A C G T A A A A C C C C G G G G T T T T T T T T T T T T T T T T T T T T A C G T A C G T A C G T A C G T
Mutation
